MergerJul 14, 2026, 08:17 AM
VYNE Therapeutics and Yarrow Bioscience Detail Merger and Pipeline
AI Summary
VYNE Therapeutics Inc. announced that Yarrow Bioscience, Inc., with which VYNE is merging, published an investor presentation. The presentation details Yarrow's lead drug candidate, YB-101, an anti-TSHR antibody for Graves' Disease (GD) and Thyroid Eye Disease (TED). The reverse merger is expected to close around July 24, 2026, with the combined entity trading as NASDAQ: YARW. Yarrow has raised $200 million to date, providing a cash runway into 2028, and is initiating a Phase 2 trial for YB-101 in GD.
Key Highlights
- Yarrow Bioscience published an investor presentation detailing its business and pipeline.
- The reverse merger with VYNE Therapeutics is expected to close around July 24, 2026.
- The combined company will trade on NASDAQ under the ticker YARW.
- Yarrow has raised $200 million, providing a cash runway into 2028.
- YB-101, a potential first-in-class anti-TSHR antibody, is advancing to Phase 2 for Graves' Disease.
- Phase 2a readout for Graves' Disease is anticipated in H2 2027.
- YB-101 received Fast Track Designation from the FDA for its Graves' Disease program.
- GenSci's Phase 1 SAD in TED showed favorable safety and rapid, dose-dependent responses.
Price Impact
More from VYNE